Business Context and Reporting Period
This Form 6-K filing by Coca-Cola European Partners Plc (CCEP) is dated March 31, 2021. The document serves as an update regarding the proposed acquisition of The Coca-Cola Company's (KO) 30.8% shareholding in Coca-Cola Amatil Limited (CCL). CCEP is the world's largest Coke bottler by revenue, operating across Western Europe, while CCL operates in the Asia Pacific region.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed acquisition rather than CCEP's operational financial results for the period.
- Acquisition Structure: CCEP will acquire the entirety of KO's 30.8% stake in CCL in cash.
- Purchase Price:
- 10.8% of CCL shares at A$9.57 per share.
- Remaining 20% interest at A$10.75 per share.
- Prices are net of a declared A$0.18 per share dividend.
- Funding: The transaction will be funded entirely through debt and cash.
- Financial Position: The filing does not provide specific values for CCEP's current revenue, profit, cash flow, margins, or total debt levels.
Material Changes and Transaction Status
The primary material change is the confirmation of the full cash acquisition of KO's stake in CCL, conditional on the implementation of a Scheme. Key developments include:
- Regulatory Approval: CCEP confirmed receipt of approval from the Australian Foreign Investment Review Board (FIRB) on January 29, 2021.
- Strategic Shift: CCEP elected to acquire the remaining 20% interest in cash, aligning with its preference for debt/cash funding over other methods.
- Timetable:
- Scheme Meeting: April 16, 2021 (Indicative)
- Effective Date: April 21, 2021 (Indicative)
- Implementation Date: May 10, 2021 (Indicative)
Guidance, Outlook, and Risks
Management Commentary and Outlook: CCEP remains committed to maintaining a solid investment-grade rating and focuses on a strong deleveraging path over the next three years. The company views the acquisition as a strategic move to expand its global footprint.
Risks and Contingencies: The transaction is subject to customary conditions, including CCL Independent Shareholder approval, court approval, and regulatory approval from the Overseas Investment Office in New Zealand. The filing highlights significant forward-looking risks, including:
- Integration Risks: Potential difficulties, delays, or costs associated with integrating CCL into CCEP.
- Financing Risks: The ability to raise necessary financing for the debt-funded transaction.
- Operational Risks: Impact of the COVID-19 pandemic, UK-EU trade relations, regulatory changes regarding packaging and taxes, and supply chain disruptions.
- Market Risks: Potential negative reaction from stakeholders if the acquisition is delayed or fails.
Investor Verification Checklist
- Verify the final approval status of the Scheme Meeting and New Zealand regulatory clearance.
- Confirm the total transaction value and the specific debt instruments to be issued for funding.
- Review CCEP's most recent Form 20-F for detailed leverage ratios and cash flow statements to assess debt capacity.
- Monitor the implementation date (currently indicative May 10, 2021) for any delays.
- Assess the impact of the A$0.18 dividend deduction on the final effective purchase price per share.